Compare TG Therapeutics Inc (TGTX) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs VF Corp — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while VF Corp trades at $16.88 (market cap $6.62B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and VF Corp pays a 2.13% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | VFC | |
|---|---|---|
Market Cap | $8.26B | $6.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $59.06 | $21.55 |
52-Week Low | $26.39 | $11.66 |
Enterprise Value | $8.50B | $10.77B |
Dividend Yield | — | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VFC trades at $16.91, down 0.41% with a bearish technical signal. The company shows mixed fundamentals with declining revenue from $11.8B in 2022 to $9.5B in 2025, though recent quarters beat EPS estimates. Net income turned negative in 2025 at -$190M, but 2026 projections show recovery to $255M profit. Valuation metrics appear reasonable with P/E of 26.38 and P/S of 0.7, while analyst consensus targets $19.33 with 43% buy ratings.
VFC faces turnaround challenges with weak Vans performance and consumer headwinds, but improving margins and debt reduction provide catalysts. The stock offers potential upside to analyst targets if brand recovery continues, though execution risks remain elevated given recent volatility and competitive pressures in apparel retail.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
